MARKET

COCP

COCP

Cocrystal Pharma Inc
NASDAQ
1.250
-0.010
-0.79%
Opening 10:11 05/15 EDT
OPEN
1.230
PREV CLOSE
1.260
HIGH
1.270
LOW
1.230
VOLUME
16.61K
TURNOVER
--
52 WEEK HIGH
2.670
52 WEEK LOW
0.8588
MARKET CAP
17.23M
P/E (TTM)
-1.5981
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at COCP last week (0504-0508)?
Weekly Report · 4d ago
Weekly Report: what happened at COCP last week (0427-0501)?
Weekly Report · 05/04 09:28
Cocrystal Showcases Norovirus Candidate CDI-988 at ICAR 2026
TipRanks · 04/30 21:43
Cocrystal Pharma publishes CDI-988 norovirus antiviral presentation slides from ICAR 2026
PUBT · 04/30 21:01
Cocrystal Pharma Features Mechanism Of Action And Clinical Advancement Of Oral Protease Inhibitor CDI-988 In Oral Presentation At 39th ICAR 2026
Benzinga · 04/30 20:25
Cocrystal Pharma advances CDI-988 into Phase 1b norovirus human challenge trial
PUBT · 04/30 20:22
Cocrystal Pharma Presentation at ICAR 2026 Highlights Mechanism of Action and Clinical Advancement of CDI-988 for the Prevention and Treatment of Norovirus Infection
Barchart · 04/30 15:05
Weekly Report: what happened at COCP last week (0420-0424)?
Weekly Report · 04/27 09:29
More
About COCP
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), noroviruses and hepatitis C viruses (HCV). It is developing small molecule antiviral therapeutics that inhibit the essential viral replication function of RNA viruses, causing acute and chronic viral diseases. It has several candidates under development for the treatment of influenza infection. CC-42344 is a novel PB2 inhibitor, which is a preclinical lead for the treatment of pandemic and seasonal influenza A. It also develops broad-spectrum influenza antivirals targeting replication enzymes of influenza A and B strains. Its broad-spectrum antiviral drug candidate, CDI-988, is an oral treatment for SARS-CoV-2, the virus that causes COVID-19. Its CC-31244, an HCV NNI, is a pan-genotypic inhibitor of NS5B polymerase for the treatment of HCV.

Webull offers Cocrystal Pharma Inc stock information, including NASDAQ: COCP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, COCP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading COCP stock methods without spending real money on the virtual paper trading platform.